VectivBio (VECT) Competitors $16.85 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock VECT vs. APLS, NAMS, TWST, DNLI, KNSA, AGIO, RXRX, CGON, VCEL, and BEAMShould you be buying VectivBio stock or one of its competitors? The main competitors of VectivBio include Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Vericel (VCEL), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. VectivBio vs. Its Competitors Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals CG Oncology Vericel Beam Therapeutics VectivBio (NASDAQ:VECT) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Do institutionals and insiders have more ownership in VECT or APLS? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 9.7% of VectivBio shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VECT or APLS more profitable? VectivBio has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -28.83%. VectivBio's return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VectivBioN/A N/A N/A Apellis Pharmaceuticals -28.83%-99.19%-25.35% Do analysts recommend VECT or APLS? Apellis Pharmaceuticals has a consensus price target of $39.79, indicating a potential upside of 99.85%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Which has preferable earnings & valuation, VECT or APLS? VectivBio has higher earnings, but lower revenue than Apellis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVectivBio$27.34MN/A-$93.74MN/AN/AApellis Pharmaceuticals$781.37M3.20-$197.88M-$1.79-11.12 Does the media prefer VECT or APLS? In the previous week, Apellis Pharmaceuticals had 4 more articles in the media than VectivBio. MarketBeat recorded 4 mentions for Apellis Pharmaceuticals and 0 mentions for VectivBio. Apellis Pharmaceuticals' average media sentiment score of 1.12 beat VectivBio's score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment VectivBio Neutral Apellis Pharmaceuticals Positive SummaryApellis Pharmaceuticals beats VectivBio on 8 of the 13 factors compared between the two stocks. Get VectivBio News Delivered to You Automatically Sign up to receive the latest news and ratings for VECT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VECT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VECT vs. The Competition Export to ExcelMetricVectivBioMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E RatioN/A21.1628.6919.45Price / SalesN/A184.72372.4779.78Price / CashN/A41.0524.7227.47Price / BookN/A7.758.215.58Net Income-$93.74M-$55.05M$3.19B$252.81M7 Day PerformanceN/A9.69%3.60%2.11%1 Month PerformanceN/A13.80%9.61%11.87%1 Year PerformanceN/A3.55%30.04%16.61% VectivBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VECTVectivBioN/A$16.85flatN/AN/A$0.00$27.34M0.0030High Trading VolumeAPLSApellis Pharmaceuticals4.2886 of 5 stars$17.89+2.7%$39.79+122.4%-49.6%$2.19B$781.37M-9.99770NAMSNewAmsterdam Pharma2.7677 of 5 stars$20.02+2.9%$42.89+114.2%+11.6%$2.18B$45.56M-10.654TWSTTwist Bioscience4.2991 of 5 stars$36.98+3.9%$50.40+36.3%-29.3%$2.13B$312.97M-11.38990Positive NewsDNLIDenali Therapeutics4.6292 of 5 stars$14.33+0.6%$33.71+135.3%-35.7%$2.07B$330.53M-5.37430KNSAKiniksa Pharmaceuticals International3.5808 of 5 stars$27.21-2.6%$38.80+42.6%+35.8%$2.04B$423.24M-108.84220Upcoming EarningsAGIOAgios Pharmaceuticals4.4313 of 5 stars$36.28+3.0%$58.60+61.5%-14.5%$2.04B$36.50M3.23390Analyst RevisionRXRXRecursion Pharmaceuticals1.9968 of 5 stars$5.36+8.7%$7.00+30.6%-36.8%$2.00B$58.84M-3.03400High Trading VolumeCGONCG Oncology2.4361 of 5 stars$25.96-1.1%$58.67+126.0%-26.9%$2.00B$1.14M-17.1961Positive NewsGap DownVCELVericel3.7656 of 5 stars$40.17+1.9%$61.14+52.2%-17.9%$1.98B$237.22M1,339.45300News CoveragePositive NewsBEAMBeam Therapeutics2.2891 of 5 stars$20.30+5.8%$48.75+140.1%-21.2%$1.93B$63.52M-4.40510High Trading Volume Related Companies and Tools Related Companies APLS Alternatives NAMS Alternatives TWST Alternatives DNLI Alternatives KNSA Alternatives AGIO Alternatives RXRX Alternatives CGON Alternatives VCEL Alternatives BEAM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VECT) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VectivBio Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share VectivBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
